Login / Signup

Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients.

Santosh DhakalTong YuAnna YinNora PisanicZoe O DemkoAnnukka A R AntarAndrea L CoxChristopher D HeaneyYukari C ManabeSabra L Klein
Published in: Open forum infectious diseases (2022)
Antinucleocapsid (anti-N) immunoglobulin G antibody responses were lower in plasma and oral fluid after severe acute respiratory syndrome coronavirus 2 infection in vaccinated patients compared with patients infected before vaccination or infected without vaccination. This raises questions about the long-term use of anti-N antibodies as a marker for natural infection for surveillance.
Keyphrases
  • end stage renal disease
  • respiratory syndrome coronavirus
  • ejection fraction
  • sars cov
  • chronic kidney disease
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • public health
  • patient reported outcomes